Key result
Macitentan use in PAH is linked to improved functional class and 6MWD.
Why the study?
The effectiveness and safety of macitentan in pulmonary arterial hypertension patients in real-world clinical practice settings were not well described.
Does macitentan improve clinical and functional outcomes in patients with pulmonary arterial hypertension in a real-world setting?
Observational (n=13)
No
Does macitentan improve clinical and functional outcomes in patients with pulmonary arterial hypertension in a real-world setting?
Macitentan demonstrated effectiveness and safety in a real-world clinical practice setting for patients with pulmonary arterial hypertension over 12 months.
Real-world macitentan data in small PAH cohort may support tolerability; leaves open need for larger prospective validation.
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death.
No takes yet. Share an insight, caveat, or question.
Cadenas-Menéndez et al. (2017) conducted an observational in pulmonary arterial hypertension (PAH) (n=13). Macitentan was evaluated on functional class (FC), 6-minute walk distance (6MWD), and NT-proBNP plasma levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: